Genetic Analysis AS — Investor Relations & Filings

Genetic Analysis AS is a research-driven diagnostics company specializing in the human microbiome. The company develops and commercializes innovative solutions based on its proprietary GA-map® technology platform, a standardized method for characterizing gut microbiota by identifying bacterial 16S rRNA gene targets. Its key product is the GA-map® Dysbiosis Test Lx, a CE-marked in vitro diagnostic test used to identify and characterize gut bacterial imbalance (dysbiosis) in patients with Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). The company also offers research-use-only assays, such as the GA-map® MHI GutHealth test, which provides a single score to assess microbiome health. Genetic Analysis serves clinical laboratories, clinical researchers, and pharmaceutical companies by providing routine diagnostics, research tools, and co-development of companion diagnostics.